Search research articles
Contact Us
Filters
Showing results (41-50 of 44) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 44 results.
Cardiology
|
January 1, 1990
Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate
F U Beil, A Schrameyer-Wernecke, U Beisiegel, et al.
The American Journal of Medicine
|
June 6, 1994
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate
H Greten, F U Beil, J Schneider, et al.
Zeitschrift Fur Kardiologie
|
December 10, 2003
[Treatment of sudden hearing loss through Fibrinogen/LDL-apheresis. A prospective, randomized multicenter trial]
M Suckfüll, D Seidel, J Thiery, et al.
Der Internist
|
April 29, 2014
[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology]
G Klose, F U Beil, H Dieplinger, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 44) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 44 results.
Cardiology
|
January 1, 1990
Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate
F U Beil, A Schrameyer-Wernecke, U Beisiegel, et al.
The American Journal of Medicine
|
June 6, 1994
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate
H Greten, F U Beil, J Schneider, et al.
Zeitschrift Fur Kardiologie
|
December 10, 2003
[Treatment of sudden hearing loss through Fibrinogen/LDL-apheresis. A prospective, randomized multicenter trial]
M Suckfüll, D Seidel, J Thiery, et al.
Der Internist
|
April 29, 2014
[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology]
G Klose, F U Beil, H Dieplinger, et al.
Page
of 5